SCHEMBL2601628

SCHEMBL2601628

CCOC(=O)/C(=C\N)C(=O)c1ccc(F)c(OC)c1C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.42
MEN1 O00255 6/20 0.42
KMT2A Q03164 6/20 0.42
NPSR1 Q6W5P4 6/20 0.42
LMNA P02545 4/20 0.42
CYP1A2 P05177 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
PLIN1 O60240 1/20 0.39
POLB P06746 1/20 0.39
PLIN5 Q00G26 1/20 0.39
ABHD5 Q8WTS1 1/20 0.39
S1PR4 O95977 1/20 0.36
S1PR1 P21453 1/20 0.36
MAPK1 P28482 1/20 0.36
MEP1B Q16820 1/20 0.36
DHODH Q02127 2/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2D6 P10635 1/20 0.35
GAA P10253 3/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2605611 0.90 MAPT (0.42) MAPTMEN1KMT2ANPSR1LMNA
SCHEMBL14015606 0.85 KMT2A (0.40) MAPTMEN1KMT2ANPSR1LMNA
SCHEMBL2601631 0.85 KMT2A (0.40) MAPTMEN1KMT2ANPSR1LMNA
SCHEMBL12219484 0.80 MAPT (0.36) MAPTMEN1KMT2ANPSR1LMNA
SCHEMBL15241560 0.80 MEN1 (0.39) MAPTMEN1KMT2ANPSR1LMNA
SCHEMBL12752722 0.76 MAPT (0.41) MAPTMEN1KMT2ANPSR1LMNA
SCHEMBL10544901 0.76 NPSR1 (0.42) MAPTMEN1KMT2ANPSR1LMNA
SCHEMBL10544905 0.76 NPSR1 (0.42) MAPTMEN1KMT2ANPSR1LMNA
SCHEMBL1476623 0.75 KMT2A (0.40) MAPTMEN1KMT2ANPSR1LMNA
SCHEMBL1476620 0.75 KMT2A (0.40) MAPTMEN1KMT2ANPSR1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8158798-B2 Coupling process for preparing quinolone intermediates TAIGEN BIOTECHNOLOGY CO., LTD. (TW) 2012-04-17 US disclosed
US-20090111991-A1 Coupling Process For Preparing Quinolone Intermediates ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED (IE) 2009-04-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090111991-A1 Coupling Process For Preparing Quinolone Intermediates CYP3A4, CYP4B1, CYP4X1 MAPT 4271/4885MEN1 1363/4885KMT2A 2928/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.